- Conditions
- Celiac Disease
- Interventions
- ALV003, placebo
- Drug
- Lead sponsor
- Alvine Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 79
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 70 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1633–1656
of 54,961
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis, Rheumatoid Arthritis
- Interventions
- Tailored Materials, Tailored Materials Plus Physician Feedback, Generic Materials, No Information
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
- Drug · Biological · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years to 72 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib
- Drug
- Lead sponsor
- Tarveda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more
- Conditions
- Neuroblastoma
- Interventions
- Carboplatin, Etoposide, Melphalan, Stem Cell Infusion, ClinicMACS
- Drug · Procedure · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hermansky Pudlak Syndrome, Interstitial Lung Disease
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Jesse Roman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 412
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more
- Conditions
- Femoral Neck Fractures
- Interventions
- Hip arthroplasty, Internal fixation
- Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Midwest Biomedical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Total Knee Arthroplasty, Arthroplasty of Knee
- Interventions
- Navio ™ Robotic-assisted Surgical System
- Device
- Lead sponsor
- Smith & Nephew, Inc.
- Industry
- Eligibility
- Up to 80 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- atrasentan hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN
- Interventions
- Oral THU-decitabine
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatitis Biliary, Pancreatitis Acute Biliary, Pancreatitis, Post-ERCP Pancreatitis, Post-ERCP Acute Pancreatitis, Post-ERCP Adverse Events
- Interventions
- indomethacin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Osteoporosis
- Interventions
- Patient Pamphlet
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 2,997 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms
- Interventions
- epothilone b
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Lumbar Spine Stenosis Central Canal
- Interventions
- Percutaneous Lumbar Decompression, Sham lumbar decompression
- Device
- Lead sponsor
- Napa Pain Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Napa, California
- Conditions
- Multiple Sclerosis, Lower Urinary Track Symptoms
- Interventions
- Silodosin 8 mg, Placebo
- Drug
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, oxaliplatin, capecitabine, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
- Conditions
- Glioblastoma Multiforme, Glioblastoma
- Interventions
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2042
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, nab-paclitaxel, CyberKnife
- Drug · Radiation
- Lead sponsor
- Cooper Norcross Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Myelodysplastic Syndromes
- Interventions
- decitabine, tretinoin, DNA methylation analysis, cytogenetic analysis, microarray analysis, flow cytometry, immunohistochemistry staining method
- Drug · Genetic · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Metastases, Adult
- Interventions
- health services intervention
- Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Burlington, Vermont